Giorgio Zanotti1, Matthew G Hartwig, Anthony W Castleberry, Jeremiah T Martin, Linda K Shaw, Judson B Williams, Shu S Lin, Robert D Davis. 1. 1 Division of General Surgery, Duke University Medical Center, Durham, NC. 2 Cardiothoracic Surgery, Duke University Medical Center, Durham, NC. 3 Cardiothoracic Surgery, University of Kentucky, Lexington, KY. 4 Duke Clinical Research Institute, Durham, NC. 5 Address correspondence to: Giorgio Zanotti, Duke University Medical Center, Duke South - White Zone, Box 3443, Durham, NC 27710.
Abstract
BACKGROUND: Coronary artery disease has a high prevalence among lung transplant recipients and has historically been a contraindication to transplant at many institutions. In patients with mild-to-moderate coronary artery disease (Mod-CAD) undergoing lung transplant, outcomes are not well defined. METHODS: All patients who underwent pulmonary transplantation from January 1996 through November 2010 with pretransplant coronary angiogram were included in our study. Recipients of multivisceral, redo, and lobar lung transplants and those who underwent pretransplant coronary revascularization were excluded. Patients were grouped into Mod-CAD or no-coronary artery disease group (No-CAD). Primary end point was overall survival. Secondary end points were 30-day events and the need for posttransplant coronary revascularization. RESULTS: Approximately 539 patients were included in the study: 362 in the No-CAD, 177 in the Mod-CAD group. Patients with Mod-CAD were predominantly male, older, and had a higher body mass index. No difference in either perioperative morbidity and mortality (Mod-CAD, 4.2% vs. No-CAD 3.3%, P=0.705) or late overall mortality was shown between groups. Mod-CAD patients had a shorter hospitalization (median: 12 days vs. 14 days, P=0.009) and required a higher rate of late coronary revascularization procedures (PCI: Mod-CAD vs. No-CAD, 0.3% vs. 4.0%, P=0.0035; CABG: Mod-CAD vs. No-CAD, 0.3% vs. 2.3%, P=0.0411). CONCLUSIONS: Mod-CAD does not appear to be associated with increased perioperative morbidity or decreased survival after transplant. Coronary artery disease may worsen and require coronary revascularization in patients with risk factors for disease progression. In these patients, close follow-up and screening for progression of coronary artery disease may help prevent late cardiac morbidity.
BACKGROUND:Coronary artery disease has a high prevalence among lung transplant recipients and has historically been a contraindication to transplant at many institutions. In patients with mild-to-moderate coronary artery disease (Mod-CAD) undergoing lung transplant, outcomes are not well defined. METHODS: All patients who underwent pulmonary transplantation from January 1996 through November 2010 with pretransplant coronary angiogram were included in our study. Recipients of multivisceral, redo, and lobar lung transplants and those who underwent pretransplant coronary revascularization were excluded. Patients were grouped into Mod-CAD or no-coronary artery disease group (No-CAD). Primary end point was overall survival. Secondary end points were 30-day events and the need for posttransplant coronary revascularization. RESULTS: Approximately 539 patients were included in the study: 362 in the No-CAD, 177 in the Mod-CAD group. Patients with Mod-CAD were predominantly male, older, and had a higher body mass index. No difference in either perioperative morbidity and mortality (Mod-CAD, 4.2% vs. No-CAD 3.3%, P=0.705) or late overall mortality was shown between groups. Mod-CADpatients had a shorter hospitalization (median: 12 days vs. 14 days, P=0.009) and required a higher rate of late coronary revascularization procedures (PCI: Mod-CAD vs. No-CAD, 0.3% vs. 4.0%, P=0.0035; CABG: Mod-CAD vs. No-CAD, 0.3% vs. 2.3%, P=0.0411). CONCLUSIONS: Mod-CAD does not appear to be associated with increased perioperative morbidity or decreased survival after transplant. Coronary artery disease may worsen and require coronary revascularization in patients with risk factors for disease progression. In these patients, close follow-up and screening for progression of coronary artery disease may help prevent late cardiac morbidity.
Authors: Richard Lee; Bryan F Meyers; Thoralf M Sundt; Elbert P Trulock; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2002-12 Impact factor: 5.209
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2012-10 Impact factor: 10.247
Authors: Manesh R Patel; Gregory J Dehmer; John W Hirshfeld; Peter K Smith; John A Spertus Journal: J Am Coll Cardiol Date: 2012-01-30 Impact factor: 24.094
Authors: Aditya K Kaza; Jeffrey F Dietz; John A Kern; David R Jones; Mark K Robbins; Steven M Fiser; Stewart M Long; James D Bergin; Irving L Kron; Curtis G Tribble Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: D W Leibowitz; A L Caputo; G C Shapiro; L L Schulman; C C McGregor; M R Di Tullio; A Schwartz; C R Smith; S Homma Journal: J Heart Lung Transplant Date: 1994 Jul-Aug Impact factor: 10.247
Authors: A W Castleberry; J T Martin; A A Osho; M G Hartwig; Z A Hashmi; G Zanotti; L K Shaw; J B Williams; S S Lin; R D Davis Journal: Am J Transplant Date: 2013-09-18 Impact factor: 8.086
Authors: Robert M Reed; Michael Eberlein; Reda E Girgis; Salman Hashmi; Aldo Iacono; Steven Jones; Giora Netzer; Steven Scharf Journal: Am J Med Date: 2012-09-06 Impact factor: 4.965
Authors: M J Henzlova; M L Padilla; A Freilich; A L Gass; M C Courtney; J A Diamond; J Machac Journal: J Heart Lung Transplant Date: 1995 Mar-Apr Impact factor: 10.247
Authors: Andrew W Murray; Michael L Boisen; Ashley Fritz; J Ross Renew; Archer Kilbourne Martin Journal: J Thorac Dis Date: 2021-11 Impact factor: 2.895